SCHEMBL1223959

SCHEMBL1223959

COc1ccc2nc(C)cc(OS(=O)(=O)C(F)(F)F)c2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.52
KDM4E B2RXH2 3/20 0.52
HSD17B10 Q99714 3/20 0.52
HPGD P15428 2/20 0.52
ALDH1A1 P00352 2/20 0.52
RAD52 P43351 1/20 0.50
KCNH2 Q12809 3/20 0.49
PTPN11 Q06124 1/20 0.49
NQO2 P16083 1/20 0.49
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
PKM P14618 1/20 0.47
ATM Q13315 1/20 0.46
SLC2A1 P11166 1/20 0.46
TP53 P04637 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MITF O75030 1/20 0.44
LMNA P02545 1/20 0.44
CFTR P13569 1/20 0.44
BLM P54132 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13209990 0.84 KDM4E (0.41) KDM4EHSD17B10ALDH1A1ATMSMN1; SMN2
SCHEMBL26632748 0.83 MAPT (0.46) POLBKDM4EALDH1A1KCNH2MEN1
SCHEMBL632944 0.82 LMNA (0.52) KDM4EMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL13209743 0.81 CYP1A2 (0.47) POLBKDM4EHSD17B10MEN1KMT2A
SCHEMBL9907552 0.80 GAA (0.54) KDM4EHSD17B10HPGDALDH1A1KCNH2
SCHEMBL29923720 0.80 POLB (0.33) POLBKDM4EHSD17B10HPGDALDH1A1
SCHEMBL1304599 0.78 MTNR1A (0.41) KDM4EHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL9909197 0.76 ALDH1A1 (0.54) KDM4EHSD17B10HPGDALDH1A1MEN1
SCHEMBL15417657 0.76 L3MBTL1 (0.41) ALDH1A1KMT2APKMSMN1; SMN2
SCHEMBL124046 0.76 MTNR1A (0.47) NQO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2144910-B1 OXAZOLIDINONE ANTIBIOTICS ACTELION PHARMACEUTICALS LTD (CH) 2015-10-28 EP disclosed
EP-2915813-A1 Oxazolidinone antibiotics Actelion Pharmaceuticals Ltd. (CH) 2015-09-09 EP disclosed
EP-2905283-A1 Oxazolidinone antibiotics Actelion Pharmaceuticals Ltd. (CH) 2015-08-12 EP disclosed
US-8217029-B2 Oxazolidinone antibiotics ACTELION PHARMACEUTICALS LTD (CH) 2012-07-10 US disclosed
US-20110039823-A1 OXAZOLIDINONE ANTIBIOTICS ACTELION PHARMACEUTICALS LTD (CH) 2011-02-17 US disclosed
EP-2144910-A2 OXAZOLIDINONE ANTIBIOTICS Actelion Pharmaceuticals Ltd. (CH) 2010-01-20 EP disclosed
WO-2008126034-A2 OXAZOLIDINONE ANTIBIOTICS ACTELION PHARMACEUTICALS LTD (CH) 2008-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039823-A1 OXAZOLIDINONE ANTIBIOTICS OXA1L, XDH, UBE2D3 POLB 536/4885KDM4E 2283/4885HSD17B10 948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.